NeuroDerm Ltd.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
dopamine precursorSmall molecule
Parkinson's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2025Complete response letterND0612Second FDA Complete Response Letter for ND0612
US, FDA · Tanabe Pharma / NeuroDerm · Source ↗

Financial reports

No financial reports recorded.